Abstract 5585: Phase I clinical trial of continuous infusion of tyroserleutide in patients with advanced hepatocellular carcinoma
| Autor: | Chen Xiao-ping, Xiao Zhen-Yu, Jia Jinbin |
|---|---|
| Rok vydání: | 2012 |
| Předmět: | |
| Zdroj: | Cancer Research. 72:5585-5585 |
| ISSN: | 1538-7445 0008-5472 |
| DOI: | 10.1158/1538-7445.am2012-5585 |
| Popis: | Hepatocellular carcinoma (HCC) is usually diagnosed in advanced stage, which causes difficulty of using surgical treatment. Previous studies demonstrated that tyroserleutide (YSL), an immunologically active tripeptide compound, could suppress the proliferation and tumor formation of some liver cancer cell lines. We aimed to investigate the feasibility and toxicity of continuous administration of YSL by a portable infusion pump to patients with advanced HCC and its biologically effective but non-toxic doses used in outpatient setting. Forty patients (12 in stage 1, 28 in stage 2, total 10 treated in each dose cohort) were treated with YSL 6, 12, 18 or 24 mg/d lasting for 5 days. No treatment-related mortality was observed. The overall response rates were 25% (3/12) and 7.2% (2/28) in stages 1 and 2 respectively. The median 6-month overall survival (OS) in stage 1 were 75, 64, and 41 days for 6, 18, and 24 mg/d groups respectively; all patients survived in the 12 mg/d group. The median OS in stage 2 were 68, 72, and 60 days for 12, 18, and 24 mg/d groups respectively; all survived in the 6 mg/d group. The most common adverse reactions were abnormal liver function (59/107) and hemogram (22/107). The dose limiting toxicities of 24 mg/d group contained abdominal distention (1/10), sicchasia (1/10), hyponatremia (1/10), myocardiac ischemia (1/10), and abnormal hemogram (6/10). We conclude that the continuous administration of YSL by portable infusion pump was well tolerated. Treatment responses of doses 6 and 12 mg/d were better than other two groups. Further studies of continuous infusion of YSL to determine its efficacy are warranted. Keywords tyroserleutide • hepatocellular carcinoma • clinical trial • portable infusion pump [Supported by China Postdoctoral Science Foundation-funded project (No. 20080440077 and 200902203)] Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5585. doi:1538-7445.AM2012-5585 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|